ページ3 - 最高の白血病化学療法医師 - トップ97名の医師

Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.

He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.

His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.

Dr. Eckhart Weidemann is one of best non hodgkin lymphoma doctors. He heads the Hematology sector of Nordwest Clinic specializing in blood disorder treatment. The professor has over 30 years of practice.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Dr. Iris Kventsel, MD, is a pediatric hemato-oncologist and bone marrow transplant (BMT) specialist at Sheba Medical Center. She is an attending physician in the Pediatric Hemato-Oncology and BMT Division at the Edmond and Lily Safra Children’s Hospital. Her clinical focus is pediatric sarcomas, including Ewing sarcoma, osteosarcoma, and rhabdomyosarcoma.

She provides multidisciplinary care, including transplant and cellular therapies. She also uses current chemotherapy protocols and targeted therapies for complex childhood cancers.

Her research focuses on genetic cancer predisposition, including Li-Fraumeni syndrome, and cancer susceptibility genes. She has published in pediatric oncology, stem cell biology, and surgical oncology (HIPEC). She is on the academic staff at Tel Aviv University. Education: MD, Technion; Pediatrics residency, Assaf HaRofeh; Pediatric Hemato-Oncology fellowship, Sheba.

イスラエルの肺癌免疫療法の第一人者。内科、呼吸器科、腫瘍内科の専門家。

ペレッド教授は、肺癌における個別化医療と免疫腫瘍学、および疾患の診断に用いる新技術に注力している。彼はダビドフ癌センターの胸部癌ユニットの責任者であり、シーバ医療センターにおける胸部悪性腫瘍の研究と発見ユニットの責任者も務めている。2010年、ペレッド教授は米国臨床腫瘍学会（ASCO）からMERIT賞を受賞しました。

職務経験:

• シニア呼吸器科医および肺がん専門医 - ヘルツリヤ医療センター
• 2011年〜現在: 呼吸器科医・腫瘍内科医、ダビドフ癌センター、イスラエル
• 2008年〜2010年: 肺癌フェローシップ (フルブライト賞; IASLC賞; ASCO Merit賞)、コロラド大学デンバー校、米国デンバー。指導者: ポール・A・バン教授、フレッド・R・ハーシュ教授
• 2007年〜2008年: 臨床腫瘍学専門研修。ダビドフ癌センター、イスラエル
• 2005年〜2007年: 呼吸器学専門研修; ラビン医療センター、イスラエル
• 2000年〜2003年: 内科専門研修; ラビン医療センター、イスラエル
• 1999年: ベトナムでのボランティア人道ミッション
• 1994年〜1998年: IDFの医療サービス医師

会員資格:

• 欧州呼吸器学会 (ERS) の胸部腫瘍学会のメンバー
• 国際肺癌研究協会 (IASLC) の早期発見・予防委員会の議長

リンパ腫と慢性リンパ性白血病の専門家として、彼と彼のチームは、血液疾患の分析とこの種の病気の新しい治療のための新技術の革新を達成しました。

ボッシュ教授は、慢性リンパ性白血病(CLL)の分野で世界的に最も評価の高い指導者の一人であり、CLLおよび他のリンパ増殖性疾患に関する臨床および基礎研究を行い、特にCLLの分子病態発生と新しい治療アプローチの開発に焦点を当てています。

ボッシュ教授は現在、フェーズ1からフェーズ3までの80以上の研究を進めており、それによりボッシュ教授の研究により、今後数年間で新しい薬剤と適応症が利用可能になることを意味しています。

教育

• 1988年にバルセロナ大学医学部を卒業。
• 1997年にバルセロナ大学で、慢性リンパ増殖性疾患におけるシグリンD1の過剰発現を研究し、イライアス・カンポ教授の指導の下で博士号を取得。
• ニューヨークのコロンビア大学がん遺伝学研究所でリッカルド・ダラ＝ファヴェラ教授の研究室で2年間の博士後研究。
• 2000年にバルセロナ・クリニック病院で慢性リンパ性白血病(LLC)の研究者。

キャリア

• 慢性リンパ性白血病の研究のためのスペイングループ（GELLC）の会長で、臨床試験分野を率いています。
• 1995年以降、CLLに関する臨床試験の開発に関与し、CLLの予後と治療の評価に多くの貢献をしています。
• 2004年からIOBオンコロジー研究所の血液学部長。
• 2009年からバルセロナのバル・デブロン大学病院の血液学部長および実験血液学研究室のディレクター。

出版物

• 「The New England Journal of Medicine」、「Nature Medicine」、「Cancer Cell」、「Blood」、「Journal of Clinical Oncology」、「Leukemia」など、権威ある科学誌に100以上の記事を発表しました。
• CLLおよび他のリンパ増殖性疾患に関するいくつかのレビューおよび書籍の章の共著者。

教育活動

バルセロナのバル・デブロン大学病院の血液学教授。

Prof. Myriam Ben Arush is a Director of Pediatric Division at Ruth Rappaport Children’s Hospital (Rambam). The Professor is an internationally recognized specialist in the field of Pediatric Oncology and Bone Marrow Transplantation.

Awards:

• the Ministry of Health Prize for the outstanding work
• the Chevalier de la Legion d’Honneur in France
• is named as one of the world most caring doctors by the World Medical Association.

Prof. Myriam Ben Arush is a member of the children’s oncology group in the USA and several European cancer societies.

Radiotherapy Specialist, Oncologist

Tamar Jablonski-Perec is an oncologist at the Hadassah Medical Center who received her Doctor of Medical Sciences at the Hebrew University in Jerusalem and completed an internship at the renowned Sloan-Kettering Cancer Center in New York. Her key takeaways include:

• Head of Institute of Oncology in 1994
• Head of Breast Cancer Treatment Center in 1998
• Professor of the Department of Oncology at the Hebrew University in 2006
• Member of several international cancer communities
• Awarded a scholarship from the Hadassah Medical School

Oncohematologist

Dr. Mahmoud M. El Zembely is a pediatric oncologist and malignant hematologist. He manages acute lymphoblastic leukemia, acute myeloid leukemia, and chronic myeloid leukemia. He treats Hodgkin and non‑Hodgkin lymphomas, nephroblastoma, neuroblastoma, and bone and liver tumors. His work includes gonadal and extragonadal germ cell tumors, rhabdomyosarcoma, and non‑rhabdomyosarcoma soft tissue sarcomas. He also cares for rare cancers and survivorship.

Accreditations: M.B.B.Ch, Assiut University, 2006. Master’s in Pediatric Oncology and Malignant Hematology, 2011. Clinical fellowship in pediatric bone marrow transplantation, Seattle Cancer Care Alliance, 2015–2017. Doctorate, 2020.

Roles: South Egypt Cancer Institute–Assiut University: Pediatric Oncology, 2008–2012. Assistant Lecturer, 2012–2019. Lecturer, 2020–2024. Shefa Al‑Orman Cancer Center, Luxor: Head of Pediatric Oncology, 2020–present.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Dr. Hila Magen, MD, leads the Multiple Myeloma and Amyloidosis Unit at Sheba Medical Center. She is a hemato-oncologist with over 35 years of experience. She is a leading Israeli expert in multiple myeloma and plasma cell disorders.

She runs a program that provides personalized care and early access to clinical trials. This includes CAR-T therapy for high-risk and relapsed or refractory myeloma and amyloidosis. Dr. Magen is a principal investigator in point-of-care CAR-T studies. She brings new immunotherapies into routine care.

Training: Fellowships in Multiple Myeloma (UAMS) and Lymphocytic Leukemia (MD Anderson). Academic: Instructor, Tel Aviv University. Research: Author of 100+ publications, contributor to landmark myeloma studies, and reviewer for international journals.

Oncologist, Radiologist

Chief Physician of the Oncology Center, Oncologist